Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema AttacksBusiness Wire • 08/05/21
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVieBusiness Wire • 08/01/21
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/31/21
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine CandidateGlobeNewsWire • 07/30/21
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline ProgressBusiness Wire • 07/30/21
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda's Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)Business Wire • 07/28/21
Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding DisordersBusiness Wire • 07/20/21
Moderna partners with Takeda, Japanese government on additional 50 million COVID-19 vaccine dosesMarket Watch • 07/20/21
Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna's COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022Business Wire • 07/20/21
New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid CongressBusiness Wire • 07/10/21
European Patient Survey finds Crohn's Disease Patients Living with Perianal Fistulas Experience a More Significant Negative Impact on Their Quality of Life than Crohn's Disease Patients without Perianal FistulasBusiness Wire • 07/09/21
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020Business Wire • 06/29/21
Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient communityPRNewsWire • 06/09/21
Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (SOT) Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)Business Wire • 06/07/21
Takeda's Dengue Vaccine Effective In Reducing Hospitalization Regardless Of Prior InfectionBenzinga • 05/24/21